Compendium of Cancer Genome Aberrations

HAEM5:ALK-negative anaplastic large cell lymphoma: Difference between revisions

(View all pending changes)
[pending revision][pending revision]
← Older editNewer edit →
VisualWikitext
Line 489: Line 489:
|TSG
|TSG
|23%<ref name=":6" />
|23%<ref name=":6" />
|N/A
|No
|N/A
|N/A
|No
|No
Line 497: Line 497:
|-
|-
|''STAT3''
|''STAT3''
|
|Oncogene
|26%<ref name=":6" />
|26%<ref name=":6" />
|N/A
|No
|N/A
|N/A
|No
|No
|Yes
|Yes
|No
|No
|
|Not seen in PTCL-NOS<ref name=":2" /> or ALK+ ALCL<ref name=":2" /><ref name=":6" />
|-
|-
|''JAK1''
|''JAK1''
|
|Oncogene
|26%<ref name=":6" />
|26%<ref name=":6" />
|No
|N/A
|N/A
|No
|Yes
|No
|Not seen in PTCL-NOS<ref name=":2" /> or ALK+ ALCL<ref name=":2" /><ref name=":6" />
|-
|PRDM1/BLIMP1<ref name=":5" />
|TSG
|6%
|No
|N/A
|N/A
|No
|No
|Yes
|No
|No
|
|-
|[[NOTCH1]]<ref name=":16" />
|Oncogene
|15%
|No
|No
|No
|No
|No
|
|-
|KMT2D<ref name=":6" />
|TSG
|20%
|No
|No
|No
|No
|No
|No
|
|
Line 541: Line 571:
|
|
|-
|-
|[[NOTCH1]]<ref>{{Cite journal|last=Larose|first=Hugo|last2=Prokoph|first2=Nina|last3=Matthews|first3=Jamie D.|last4=Schlederer|first4=Michaela|last5=Högler|first5=Sandra|last6=Alsulami|first6=Ali F.|last7=Ducray|first7=Stephen P.|last8=Nuglozeh|first8=Edem|last9=Fazaludeen|first9=Feroze M. S.|date=2020-04-23|title=Whole Exome Sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target|url=https://haematologica.org/article/view/9725|journal=Haematologica|language=en|doi=10.3324/haematol.2019.238766|issn=1592-8721}}</ref>
|[[NOTCH1]]<ref name=":16">{{Cite journal|last=Larose|first=Hugo|last2=Prokoph|first2=Nina|last3=Matthews|first3=Jamie D.|last4=Schlederer|first4=Michaela|last5=Högler|first5=Sandra|last6=Alsulami|first6=Ali F.|last7=Ducray|first7=Stephen P.|last8=Nuglozeh|first8=Edem|last9=Fazaludeen|first9=Feroze M. S.|date=2020-04-23|title=Whole Exome Sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target|url=https://haematologica.org/article/view/9725|journal=Haematologica|language=en|doi=10.3324/haematol.2019.238766|issn=1592-8721}}</ref>
|Activating
|Activating
|15%
|15%
Line 575: Line 605:
!Gene; Genetic Alteration!!Pathway!!Pathophysiologic Outcome
!Gene; Genetic Alteration!!Pathway!!Pathophysiologic Outcome
|-
|-
|EXAMPLE: BRAF and MAP2K1; Activating mutations
|''STAT3''<ref name=":2" />
|EXAMPLE: MAPK signaling
|JAK-STAT pathway
|EXAMPLE: Increased cell growth and proliferation
|Increased cell growth and proliferation
|-
|-
|EXAMPLE: CDKN2A; Inactivating mutations
|''NFkB2-ROS1'' fusion<ref name=":2" />
|EXAMPLE: Cell cycle regulation
|JAK-STAT pathway
|EXAMPLE: Unregulated cell division
|Increased cell growth and proliferation
|-
|-
|EXAMPLE:  KMT2C and ARID1A; Inactivating mutations
|''NFkB2-TYK2'' fusion<ref name=":2" />
|EXAMPLE:  Histone modification, chromatin remodeling
|JAK-STAT pathway
|EXAMPLE:  Abnormal gene expression program
|Increased cell growth and proliferation
|}
|}


Retrieved from "https://test.ccga.io/index.php/HAEM5:ALK-negative_anaplastic_large_cell_lymphoma"